Access to Advanced Health Institute (AAHI)
Michael Davis, Ph.D. is a senior scientist with significant experience in the field of cancer biology and immunology. With a background in RNA vaccines and tumor suppressors, Michael has made key contributions in understanding innate immune pathways in response to infections like SARS-CoV-2 and developing treatments for melanoma. Michael's research has focused on elucidating cellular mechanisms driving cell death and inflammation, with a strong academic foundation from Vanderbilt University and extensive work experience at research institutions like the Fred Hutchinson Cancer Research Center and the University of Washington.
Access to Advanced Health Institute (AAHI)
AAHI is a nonprofit biotech research institute located in Seattle, Washington that combines the high-quality science of an academic research organization with the product-development capabilities of a biotech company to help combat some of the world’s deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the body’s natural response to disease. Through collaborations AAHI brings innovation from the lab to the clinic to the people, furthering AAHI’s mission to bring together the best experts, technologies, and platforms to create accessible, high-quality products and solutions. AAHI is working to build a world in which every person has access to tools that harness their immune system and allow them to live a healthy life free of illness and disease.